India’s Biocon could fill gap created by reported Novo insulin pen retreat which risks drug access to kids with diabetes
May 13, 2025 – (Bloomberg) — Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless non-patented drugmakers such as Biocon Ltd. step in to plug the gap in a $34 billion market. The Danish …